Emerging Role for Bevacizumab in Combination With Chemotherapy for Patients With Platinum-Resistant Ovarian Cancer

Journal of Clinical Oncology - United States
doi 10.1200/jco.2013.54.7299
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab

Clinical Medicine Insights: Oncology
Oncology
2019English

A Phase II Study of the Combination Chemotherapy of Bevacizumab and Gemcitabine in Women With Platinum-Resistant Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2020English

Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched With Patients Treated With Parenteral Chemotherapy

Anticancer Research
MedicineCancer ResearchOncology
2016English

Prm212 - Patient Experience With Platinum-Resistant or Platinum-Refractory Ovarian Cancer

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Chemotherapy-Free Strategy for Platinum-Sensitive Recurrent Ovarian Cancer

The Lancet Oncology
Oncology
2019English

Targeted Treatment of Recurrent Platinum-Resistant Ovarian Cancer: Current and Emerging Therapies

Cancer Management and Research
Oncology
2010English

Veliparib and Topotecan for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With BRCA Negative or Unknown BRCA Status

Cancer Treatment and Research Communications
Cancer ResearchOncology
2018English

Oral Melphalan as a Treatment for Platinum-Resistant Ovarian Cancer

British Journal of Cancer
Cancer ResearchOncology
2003English

Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients With Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy